Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
Funding Opportunity RFA-DK-19-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers. CF Research and Translation Core Centers are designed to support both basic and clinical research on Cystic Fibrosis. CF Research and Translation Core Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program. Core Centers provide shared resources to support research to develop and test new therapies for CF ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 21, 2019 Category: Research Source Type: funding

Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers. CF Research and Translation Core Centers are designed to support both basic and clinical research on Cystic Fibrosis. CF Research and Translation Core Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program. Core Centers provide shared resources to support research to develop and test new therapies for CF and to foster collaborations among institutions with a strong existing research ...
Source: NIDDK Funding Opportunities - March 21, 2019 Category: Endocrinology Source Type: funding

Patient Reported Outcomes Tool Development for Use in Non-Cystic Fibrosis Bronchiectasis Clinical Trials (U01- Clinical Trial Required)
Funding Opportunity RFA-FD-19-014 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support research to develop and qualify a Patient Reported Outcome (PRO) for Non-Cystic Fibrosis Bronchiectasis (NCFB) under FDAs Drug Development Tools Qualification Program. This would include the qualitative phase of developing the instrument, quantitative phase of testing the instrument, and qualification of the instrument. It is expected that this qualified PRO would help improve upon the current design, conduct, and interpretation of anti-infective clinical trials in NCFB pa...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 6, 2019 Category: Research Source Type: funding

Patient Reported Outcomes Tool Development for Use in Non-Cystic Fibrosis Bronchiectasis Clinical Trials (U01) Clinical Trial Optional
Funding Opportunity RFA-FD-19-005 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support research to develop and qualify a Patient Reported Outcome (PRO) for Non-Cystic Fibrosis Bronchiectasis (NCFB) under FDAs Drug Development Tools Qualification Program. This would include the qualitative phase of developing the instrument, quantitative phase of testing the instrument, and qualification of the instrument. It is expected that this qualified PRO would help improve upon the current design, conduct, and interpretation of anti-infective clinical trials in NCFB pa...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 30, 2019 Category: Research Source Type: funding

Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Clinical Centers (U01 Clinical Trial Required)
Funding Opportunity RFA-DK-18-501 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN is composed of a Scientific and Data Coordination Center (SDCC) and Clinical Centers (CC). ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; B...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 18, 2018 Category: Research Source Type: funding

Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Scientific and Data Coordinating Center (U24 Clinical Trial Optional)
Funding Opportunity RFA-DK-18-502 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN will be composed of a Scientific and Data Coordination Center (DCC), Clinical Centers (CC) , and the NIDDK/NIH as the sponsor of the Network. ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progres...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 18, 2018 Category: Research Source Type: funding

Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Scientific and Data Coordinating Center (U24 Clinical Trial Optional)
The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN will be composed of a Scientific and Data Coordination Center (DCC), Clinical Centers (CC) , and the NIDDK/NIH as the sponsor of the Network. ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; M...
Source: NIDDK Funding Opportunities - September 18, 2018 Category: Endocrinology Source Type: funding

Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChiLDReN) Clinical Centers (U01 Clinical Trial Required)
The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN is composed of a Scientific and Data Coordination Center (SDCC) and Clinical Centers (CC). ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; Mitochondrial hepatopathies; Idiopathic Neonatal Hep...
Source: NIDDK Funding Opportunities - September 18, 2018 Category: Endocrinology Source Type: funding

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed)
Funding Opportunity PA-18-741 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 3, 2018 Category: Research Source Type: funding

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this prog...
Source: NIDDK Funding Opportunities - April 3, 2018 Category: Endocrinology Source Type: funding

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Optional)
Funding Opportunity PA-18-052 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 15, 2017 Category: Research Source Type: funding

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this prog...
Source: NIDDK Funding Opportunities - November 15, 2017 Category: Endocrinology Source Type: funding

Cystic Fibrosis Research and Translation Center (P30)
Funding Opportunity RFA-DK-17-007 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers. CF Research and Translation Core Centers are designed to support both basic and clinical research on Cystic Fibrosis. CF Research and Translation Core Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program. Core Centers provide shared resources to support research to develop and test new therapies for CF ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 3, 2017 Category: Research Source Type: funding

Cystic Fibrosis Research and Translation Center (P30)
This Funding Opportunity Announcement (FOA) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers. CF Research and Translation Core Centers are designed to support both basic and clinical research on Cystic Fibrosis. CF Research and Translation Core Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program. Core Centers provide shared resources to support research to develop and test new therapies for CF and to foster collaborations among institutions with a strong existing research ...
Source: NIDDK Funding Opportunities - May 3, 2017 Category: Endocrinology Source Type: funding

Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)
Funding Opportunity Number: PAR-16-121 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: Food and NutritionHealthCFDA Number: 93.847Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the...
Source: Grants.gov - March 10, 2016 Category: Research Tags: Food and Nutrition Health Source Type: funding

Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)
Funding Opportunity PAR-16-121 from the NIH Guide for Grants and Contracts. The overarching goal of this Funding Opportunity Announcement (FOA) is to translate basic science research into knowledge and tools that can be utilized to provide strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, hematolog...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 9, 2016 Category: Research Source Type: funding

Pilot and Feasibility Clinical Research Grants in Diabetes, and Endocrine and Metabolic Diseases (R21)
Funding Opportunity Number: PA-12-157 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: Food and NutritionHealthCFDA Number: 93.847Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the ...
Source: Grants.gov - April 7, 2015 Category: Research Tags: Food and Nutrition Health Source Type: funding

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21)
Funding Opportunity Number: PA-15-169 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: Food and NutritionHealthCFDA Number: 93.847Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the ...
Source: Grants.gov - April 3, 2015 Category: Research Tags: Food and Nutrition Health Source Type: funding

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21)
Funding Opportunity PA-15-169 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 1, 2015 Category: Research Source Type: funding

Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium (U19)
Funding Opportunity Number: RFA-AR-15-014 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCFDA Number: 93.846Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with th...
Source: Grants.gov - March 6, 2015 Category: Research Tags: Health Source Type: funding

Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium (U19)
Funding Opportunity RFA-AR-15-014 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications for the Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium. The NIAMS, on behalf of the National Institutes of Health, intends to capitalize on recent advances in the science of Patient Reported Outcomes (PROs) to measure the patient experience in clinical care and research in children with a variety of chronic diseases and conditions (e.g., asthma, juvenile arthritis, cystic fibrosis, diabetes, obesity and overweight, chronic kidney disease, inflammatory ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 6, 2015 Category: Research Source Type: funding

Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator- Directed Therapeutics (R41)
Funding Opportunity Number: RFA-HL-15-026 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: HealthCFDA Number: 93.838Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the IRS, other tha...
Source: Grants.gov - December 4, 2014 Category: Research Tags: Health Source Type: funding

Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator- Directed Therapeutics (R43/R44)
Funding Opportunity Number: RFA-HL-15-027 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: HealthCFDA Number: 93.838Eligible Applicants Small businessesAgency Name: HHS-NIH11Closing Date: Nov 09, 2016Award Ceiling: Expected Number of Awards: Creation Date: Dec 03, 2014Funding Opportunity Description: This program will support the commercial development and validation of novel in vitro human cell-based tools for predicting the responses of individual patients to cystic fibrosis transmembrane conductance regulator (CFTR)-directed therapeutics for cystic fibrosis (...
Source: Grants.gov - December 4, 2014 Category: Research Tags: Health Source Type: funding

Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator- Directed Therapeutics (R43/R44)
Funding Opportunity RFA-HL-15-027 from the NIH Guide for Grants and Contracts. This program will support the commercial development and validation of novel in vitro human cell-based tools for predicting the responses of individual patients to cystic fibrosis transmembrane conductance regulator (CFTR)-directed therapeutics for cystic fibrosis (CF) lung disease. NHLBI anticipates that outcomes of successful SBIR projects will help attract strategic partners or investors to support ultimate commercialization of a personalized medicine platform that could accelerate translation of CFTR-directed therapy in patients with CF l...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 3, 2014 Category: Research Source Type: funding

Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator- Directed Therapeutics (R41)
Funding Opportunity RFA-HL-15-026 from the NIH Guide for Grants and Contracts. This program will support the technical development and validation of novel in vitro human cell-based tools for predicting the responses of individual patients to cystic fibrosis transmembrane conductance regulator (CFTR)-directed therapies for cystic fibrosis (CF) lung disease. NHLBI anticipates that outcomes of successful STTR projects will help attract strategic partners or investors to support ultimate commercialization of a personalized medicine platform that could accelerate translation of CFTR-directed therapy in patients with CF lung ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 3, 2014 Category: Research Source Type: funding

2015 Allergy, Asthma & Immunology Education and Research Organization Faculty Development Award
2015 Allergy, Asthma & Immunology Education and Research Organization Faculty Development Award Letter of Intent is due October 1, 2014 Complete application is due November 15, 2014 Objective To support a junior faculty member in the specialty of allergy, asthma and immunology. Funding is to support research in basic and/or clinical allergy and immunology and to promote the specialty. Sponsor Allergy, Asthma & Immunology Education and Research Organization, Inc. (ARTrust). The mission of the ARTrust is to find treatments and cures for the millions of people suffering from allergies, asthma and other...
Source: ScanGrants feed - September 10, 2014 Category: Research Authors: Allergy, Asthma & Immunology Education and Research Organization Source Type: funding

Cystic Fibrosis Foundation Clinical Fellowships
Application Deadline for 1st & 2nd Yr Fellowships:  First Wednesday of October Application Deadline for 3rd & 4th: First Wednesday of September Application Deadline for 5th Yr Fellowships: First Wednesday of September The intent of this award is to encourage specialized training early in a physician’s career and to prepare candidates for careers in academic medicine. Training must take place in a CF Foundation-accredited care center and must encompass diagnostic and therapeutic procedures, comprehensive care and CF-related research. Applicants must be eligible for Board certification in pediatri...
Source: ScanGrants feed - April 30, 2014 Category: Research Authors: Cystic Fibrosis Foundation Clinical Fellowships Source Type: funding

Cystic Fibrosis Foundation Postdoctoral Research Fellowships
Application Deadline: First Wednesday of September These awards are offered to M.D.s, Ph.D.s, and M.D./Ph.D.s interested in conducting basic or clinical research related to cystic fibrosis. Awards are offered through the Cystic Fibrosis Foundation’s network of research centers, or through individual applications submitted to the Foundation. Stipends are $39,000 (first year), $40,100 (second year), and $42,300 (optional third year). Research expenses of $3,750 per year are available, as well.  (Indirect costs not allowed.) U.S. citizenship or permanent resident status is required. Please direct inquiries...
Source: ScanGrants feed - April 30, 2014 Category: Research Authors: Cystic Fibrosis Foundation Source Type: funding

Request for Information (RFI): Human Cellular Models as Experimental Tools to Predict Individual Responses to CFTR-directed Therapeutics for Cystic Fibrosis Lung Disease
Notice NOT-HL-14-221 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 4, 2014 Category: Research Source Type: funding

Cystic Fibrosis Foundation Research Grants
Letter of Intent Deadline: April 7, 2014 Application Deadline: September 3, 2014 to Proposal Central by 5:00 pm (EDT). This grant mechanism is intended to encourage the development of new information that contributes to the understanding of the basic etiology and pathogenesis of CF. Funding priority will be placed on those projects proposing to better understand the mechanisms behind disease pathophysiology and to develop strategies to prevent or treat it. All proposals must be hypothesis driven, and sufficient preliminary data must be provided to justify CFF support. Information derived from such studies will hopef...
Source: ScanGrants feed - March 24, 2014 Category: Research Authors: Cystic Fibrosis Foundation Source Type: funding

Developing Innovative GastoEnterology Specialty Training (DIGEST) Program
Application Deadline: April 2, 2014 Electronic submissions are accepted at grants@cff.org. The CF Foundation recognizes the growing demand for physicians trained to address the unique gastroenterologic needs of CF patients and the need for a greater GI focus in the clinical research enterprise. To expand the availability of CF-GI experts, the CF Foundation announces the Developing Innovative GastroEnterology Specialty Training (DIGEST) Program. Accordingly, the Foundation releases this Request for Applications (RFA) for training awards to physicians interested in developing expertise in the gastroenterologic care ...
Source: ScanGrants feed - March 24, 2014 Category: Research Authors: Cystic Fibrosis Foundation Source Type: funding

Cystic Fibrosis Foundation Program for Adult Care Excellence (PACE)
Application Deadline: April 7, 2014 Electronic submissions are accepted at grants@cff.org. As the average life expectancy of patients continues to increase, the CF Foundation recognizes the growing demand for physicians trained to address the unique medical needs of adult CF patients and the need for greater participation from adult care programs in the clinical research enterprise. To expand the scope of adult care programs and increase the number of adult caregivers needed, the CF Foundation will recruit another cohort of caregivers to the Program for Adult Care Excellence (PACE). Accordingly, the Foundation has...
Source: ScanGrants feed - March 24, 2014 Category: Research Authors: Cystic Fibrosis Foundation Source Type: funding

Cystic Fibrosis Foundation Harry Shwachman Clinical Investigator Award
Appication Deadline: Second Wednesday of September Application must be submitted electronically at Proposal Central by 5:00 pm (EDT). This three-year award provides the opportunity for clinically-trained physicians to develop into independent biomedical research investigators who are actively involved in CF-related areas. It is also intended to facilitate the transition from postdoctoral training to a career in academic medicine. Support is available for up to $76,000 per year plus $15,000 for supplies. (Indirect costs are not allowed.) U.S. citizenship or permanent resident status is required. Please direct inq...
Source: ScanGrants feed - March 24, 2014 Category: Research Authors: Cystic Fibrosis Foundation Source Type: funding

Cystic Fibrosis Foundation LeRoy Matthews Physician/Scientist Award
Appication Deadline: Second Wednesday of September Application must be submitted electronically at Proposal Central by 5:00 pm (EDT). This award will provide up to six years of support for outstanding, newly trained pediatricians and internists (M.D.’s and M.D./Ph.D.’s) to complete subspecialty training, develop into independent investigators, and initiate a research program. Support ranges from $48,000 (stipend) plus $10,000 (research and development) for year one, to $76,000 (stipend) plus $15,000 (research and development) for year six. (Indirect costs are not allowed.) U.S. citizenship or permanent...
Source: ScanGrants feed - March 24, 2014 Category: Research Authors: Cystic Fibrosis Foundation Source Type: funding

Cystic Fibrosis Foundation Pilot and Feasibility Awards
Letter of Intent Deadline: April 7, 2014 Application Deadline: September 10, 2014 to Proposal Central by 5:00 pm (EDT). These grants are for developing and testing new hypotheses and/or new methods, and to support promising new investigators as they establish themselves in research areas relevant to CF. Proposed work must be hypothesis driven and must reflect innovative approaches to critical questions in CF research. The award is not meant to support continuation of programs begun under other granting mechanisms. Funding priority will be placed on those projects proposing to better understand the mechanisms behin...
Source: ScanGrants feed - March 24, 2014 Category: Research Authors: Cystic Fibrosis Foundation Source Type: funding

Cystic Fibrosis Research and Translation Core Center (P30)
Funding Opportunity Number: RFA-DK-13-007 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: Food and NutritionHealthCFDA Number: 93.847Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with ...
Source: Grants.gov - January 14, 2014 Category: Research Tags: Food and Nutrition Health Source Type: funding

Cystic Fibrosis Research and Translation Core Center (P30)
Funding Opportunity RFA-DK-13-007 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers. CF Research and Translation Core Centers are designed to support both basic and clinical research on Cystic Fibrosis. CF Research and Translation Core Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program. Core Centers provide shared resources to support research to develop and test new therapies for C...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 14, 2014 Category: Research Source Type: funding

Continuation of ChiLDReN, the Childhood Liver Disease Research Network (U01)
Funding Opportunity Number: RFA-DK-13-011 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: Food and NutritionHealthCFDA Number: 93.847Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)...
Source: Grants.gov - August 1, 2013 Category: Research Tags: Food and Nutrition Health Source Type: funding

Gilead Sciences Research Scholars Program in Cystic Fibrosis
Application Deadline: July 26, 2013 The mission of the Gilead Sciences Research Scholars Program in Cystic Fibrosis is to support innovative scientific research that will advance knowledge in the fields of pediatric and adult cystic fibrosis and provide support for early research career development. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding of cystic fibrosis. The Program provides financial support to 3 junior faculty researchers for a 2-year period. Each award is funded up to $130,000, to be paid in annual installments of up to $65,000 per year for 2 years. F...
Source: ScanGrants feed - May 1, 2013 Category: Research Authors: Gilead Sciences Source Type: funding

Cystic Fibrosis Foundation Therapeutics, Inc. Clinical Research Awards
Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the CF Foundation, offers competitive awards to support clinical research projects directly related to CF treatment and care. Projects may address diagnostic or therapeutic methods related to CF or the pathophysiology of CF, and applicants must demonstrate access to a sufficient number of CF patients from CF Foundation-accredited care centers and to appropriate controls. Up to $100,000 per year (plus 8% indirects) for a maximum of three years may be requested for single-center clinical research grants. For...
Source: ScanGrants feed - January 28, 2013 Category: Research Authors: Cystic Fibrosis Foundation Therapeutics, Inc. Source Type: funding